ConductScience.org, home

Paper17569868

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

Mata-Haro V and 5 others. Science, 2007. Cited by 717 papers, by iCite.

Cite this record

ConductScience Library. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Papers, record 17569868. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17569868

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
PubMed
Journal
Science
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
717
iCite
Relative citation ratio, by iCite
15.6
iCite
Revised in PubMed
2026-01-28
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mata-Haro VVerónica
2Cekic CCaglar
3Martin MMichael
4Chilton PMPaula M
5Casella CRCarolyn R
6Mitchell TCThomas C

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adaptor Proteins, Vesicular TransportMajor topic
Adjuvants, ImmunologicMajor topic
Lipid AMajor topic
Toll-Like Receptor 4Major topic
Adoptive Transfer
Animals
Cytokines
Immunization
Lipopolysaccharides
Lymphocyte Activation
Macrophages
Mice
Mice, Inbred C57BL
Monocytes
Myeloid Differentiation Factor 88
Oligonucleotide Array Sequence Analysis
Ovalbumin
Phosphatidylinositol 3-Kinases
Signal Transduction
T-Lymphocytes

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 AI051377NIAID NIH HHSUnited StatesR01AI051377PubMed and NIHNIH RePORTER
K02 AI059023NIAID NIH HHSUnited StatesK02AI059023PubMed and NIHNIH RePORTER
AI51377NIAID NIH HHSUnited StatesR01AI051377PubMed and NIHNIH RePORTER
R01 AI071047NIAID NIH HHSUnited StatesR01AI071047PubMed and NIHNIH RePORTER
AI059023NIAID NIH HHSUnited StatesK02AI059023PubMed and NIHNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in17569850Immunology. The shape of things to come.https://conductscience.org/library/papers/17569850

Source PubMed

Download CSV of comments and corrections

Cited by481

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 717 citations.

PMIDTitleJournalYearIn PapersSource
42851384Dissecting the mechanism of action of the adjuvant system AS01 in human immune cells: synergy of QS-21 and monophosphoryl lipid A and role of type I interferons.Front Immunol2026https://conductscience.org/library/papers/42851384PubMed
42682849Pulmonarom® promotes TLR-related and interferon-related antiviral responses during influenza A (H1N1 and H3N2) infection in human monocyte-derived dendritic cells.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42682849PubMed
42657027Phosphorylation shapes antigen presentation and immune recognition: mechanistic insights and translational perspectives.Front Immunol2026https://conductscience.org/library/papers/42657027PubMed
42635620Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer-Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42635620PubMed
42618767Bacterial lipid structural diversity mediates commensalism and pathogenesis.Nat Rev Microbiol2026https://conductscience.org/library/papers/42618767PubMed
42534843Licensed and investigational TLR4 agonists as vaccine adjuvants: structural basis, clinical progress, and future directions.Front Immunol2026https://conductscience.org/library/papers/42534843PubMed
42484648Outer membrane engineering through lipid A modification allows modulation of Burkholderia pseudomallei membrane permeability and innate immune responsivity.Infect Immun2026https://conductscience.org/library/papers/42484648PubMed
42475333Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency.PLoS One2026https://conductscience.org/library/papers/42475333PubMed
42188764Plant-Based Strategies for Vaccine Development: A Narrative Review of Recombinant Biofactories, Phytochemical Adjuvants, Innovative Delivery Systems, and Insights on Oral and Edible Vaccines.Vaccines (Basel)2026https://conductscience.org/library/papers/42188764PubMed
42188757Bordetella pertussis Infection: From Immune Pathogenesis to Next-Generation Vaccines.Vaccines (Basel)2026https://conductscience.org/library/papers/42188757PubMed
42094701Adjuvant Strategies to Improve the Efficacy of Allergen Immunotherapy.J Inflamm Res2026https://conductscience.org/library/papers/42094701PubMed
41983139Monophosphoryl lipid A boosts macrophage antimicrobial immunity by metabolically regulating source-specific ROS generation.Front Immunol2026https://conductscience.org/library/papers/41983139PubMed
41837360Rational design of next-generation vaccine adjuvants: From molecular mechanisms to hybrid delivery platforms.Hum Vaccin Immunother2026https://conductscience.org/library/papers/41837360PubMed
41754498The Safety of Alcaligenes Lipid A in a Virus-Induced Immune Disease Model Associated with IgA, Th17 Cells, and Microbiota.Viruses2026https://conductscience.org/library/papers/41754498PubMed
41723190Self-destructing attenuated adjuvant Salmonella serves as a safe and potent live vaccine adjuvant.NPJ Vaccines2026https://conductscience.org/library/papers/41723190PubMed
41625474Treatment of Metastatic Cancer by Conferring Immunogenicity to the Apoptotic Bodies of the Primary Tumor.Cancer Commun (Lond)2026https://conductscience.org/library/papers/41625474PubMed
41601666Current update on toll-like receptors and prostate cancer: a decade of progress and emerging insights.Front Immunol2025https://conductscience.org/library/papers/41601666PubMed
41529396Bioprinting collagenase-responsive hydrogel for controlled release of cowpea mosaic virus immunotherapy.Biofabrication2026https://conductscience.org/library/papers/41529396PubMed
41409277From bark to bench: innovations in QS-21 adjuvant characterization and manufacturing.Front Immunol2025https://conductscience.org/library/papers/41409277PubMed
41403359Programmable Antigen-Specific Immunity via Self-Adjuvanting Nanovaccines Co-Delivering Immune Modulators.Angew Chem Int Ed Engl2026https://conductscience.org/library/papers/41403359PubMed

See all 481 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
TICAM1148022PubTator's text mininghttps://conductscience.org/library/genes/148022NCBI Gene
TLR47099PubTator's text mininghttps://conductscience.org/library/genes/7099NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17569868

GET https://conductscience.org/api/papers/v1/17569868/cited_by?page=2